Case Report

Peyronie Disease in Association with Carvedilol: A Case Report

Authors: David S. H. Bell, MB, FACE, FACP


Beta blockade is associated with the onset and progression of Peyronie disease (PD). To date, there has not been a report of PD occurring with the alpha/beta blocker carvedilol. It remains unproven but likely that carvedilol was the cause of the PD in the patient described in this case. It is hypothesized that because of carvedilol’s vasodilating alpha adrenergic receptor stimulation and its anti-inflammatory effect, PD occurs less frequently with carvedilol than with other beta blockers. However, in this case the protective properties of carvedilol, like vasodilation and the anti-inflammatory effect, may not be sufficient to overcome its vasoconstricting beta adrenergic receptor blockade.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1.Tunuguntia HS. Management of Peyronie’s disease—a review. World J Urol 2001;19:244–250.
2.Bivalacqua TS, Purohit SK, Hellstrom WJ. Peyronie’s disease: advances in basic science and pathophysiology. Curr Urol Rep 2000;1:297–301.
3.Wallis AA, Bell R, Sutherland PW. Propranolol and Peyronie’s disease. Lancet 1977;2:980.
4.Osborne DR. Propranolol and Peyronie’s disease. Lancet 1977;1:1111.
5.Paladini G. Peyronie’s disease and systemic lupus erythematosus syndrome associated with metoprolol administration: a case report. Int J Tissue React 1981;3:95–98.
6.Hambleton G, Macleod AF, Binless JT. Is Peyronie’s disease iatrogenic? J R Coll Gen Pract 1983;33:60.
7.Yasunari K, Maeda K, Nakamura M, et al. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004;16:460–465.
8.Kristensen BO. Labetalol-induced Peyronie’s disease? A case report. Acta Med Scand 1979;206:511–512.
9.Muralidhar S, Kumar B, Sharma SK, et al. Etiologic factors in Peyronie’s disease. Int J Dermatol 1997;36:579–581.
10.Reham J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 1998;51:620–626.